Glioblastoma

Pancreas cancer

Liver cancer

Breast cancer

Colorectal cancer

Lung cancer

Hematology

Regenerative therapy

Stem cells from adult tissues were considered for a long time as promising tools for regenerative therapy of neurological diseases, including spinal cord injuries (SCI).

Researchers at GIGA have investigated the impact of pure populations of mesenchymal stem cells (MSCs) and neural crest stem cells (NCSCs) isolated from adult bone marrow in a mouse model of spinal cord injury.

They observed that both cell types induced motor recovery in mice, and modified the inflammatory reaction in the lesion site.

Their preliminary results suggest that both cell types have beneficial effects in experimental SCI.

Interested in these projects? Drop us an email [info@b2h.be]. We are looking forward collaborating with you!

 

Role of elongator complex

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the brain and spinal cord. The cause of multiple sclerosis is unknown. It’s considered an autoimmune disease whereby the immune system malfunction destroys myelin. Among others, one strategy to treat MS is to stimulate the recruitment and the activation of resident oligodendrocyte precursor cells (OPCs) to differentiate them into functional myelinating cells.

In this context, researchers at GIGA are studying the role of the Elongator complex in the adult CNS demyelination and demyelination processes.

Their preliminary obtained results suggest that Elongator could play a role in the differentiation of OPCs and act as a negative regulator of the demyelination.

Interested in these projects? Drop us an email [info@b2h.be]. We are looking forward collaborating with you!

New TP receptor antagonists

Researchers at CIRM have synthesized and evaluated new series of original 2-aryloxy/arylamino-5-cyanobenzenesulfonylureas as thromboxane A2 receptor (TP receptor) antagonists.

Based on functional pharmacological test, several compounds were found to be as potent as the 2-arylamino-5-nitrobenzenesulfonylurea reference compound BM-573, supporting the view that the bio-isosteric replacement of the nitro group by a cyano group was tolerated.

TP receptor antagonist activity of the most promising molecules was confirmed in a platelet aggregation assay using the TP receptor agonist U-46619 as a pro-aggregant.

Three compounds were identified as leads for further non-clinical pharmacological and toxicological studies.

Interested in these projects? Drop us an email [info@b2h.be]. We are looking forward collaborating with you!